A detailed history of Bridges Investment Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Bridges Investment Management Inc holds 180,286 shares of ABBV stock, worth $30.2 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
180,286
Previous 181,039 0.42%
Holding current value
$30.2 Million
Previous $31.1 Million 14.66%
% of portfolio
0.5%
Previous 0.48%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$163.84 - $199.33 $123,371 - $150,095
-753 Reduced 0.42%
180,286 $35.6 Million
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $15.6 Million - $18.2 Million
100,547 Added 124.92%
181,039 $31.1 Million
Q1 2024

Apr 25, 2024

SELL
$159.82 - $182.1 $310,530 - $353,820
-1,943 Reduced 2.36%
80,492 $14.7 Million
Q4 2023

Jan 23, 2024

BUY
$137.6 - $154.97 $313,590 - $353,176
2,279 Added 2.84%
82,435 $12.8 Million
Q3 2023

Oct 24, 2023

SELL
$133.59 - $154.65 $1.88 Million - $2.17 Million
-14,047 Reduced 14.91%
80,156 $11.9 Million
Q2 2023

Jul 07, 2023

SELL
$132.51 - $164.9 $1.4 Million - $1.74 Million
-10,568 Reduced 10.09%
94,203 $12.7 Million
Q1 2023

Apr 28, 2023

BUY
$144.61 - $166.54 $101,371 - $116,744
701 Added 0.67%
104,771 $16.7 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $395,843 - $474,719
2,862 Added 2.83%
104,070 $16.8 Million
Q3 2022

Oct 21, 2022

SELL
$134.21 - $153.93 $319,956 - $366,969
-2,384 Reduced 2.3%
101,208 $13.6 Million
Q2 2022

Jul 12, 2022

SELL
$137.62 - $174.96 $550 - $699
-4 Reduced -0.0%
103,592 $15.9 Million
Q1 2022

Apr 08, 2022

BUY
$131.98 - $163.75 $6,730 - $8,351
51 Added 0.05%
103,596 $16.8 Million
Q4 2021

Feb 01, 2022

BUY
$107.43 - $135.93 $590,327 - $746,935
5,495 Added 5.6%
103,545 $14 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $84,375 - $95,778
793 Added 0.82%
98,050 $10.6 Million
Q2 2021

Jul 19, 2021

SELL
$105.21 - $117.21 $119,413 - $133,033
-1,135 Reduced 1.15%
97,257 $11 Million
Q1 2021

May 05, 2021

SELL
$102.3 - $112.62 $292,782 - $322,318
-2,862 Reduced 2.83%
98,392 $10.6 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $693,984 - $936,952
-8,622 Reduced 7.85%
101,254 $10.8 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $170,101 - $199,643
-1,980 Reduced 1.77%
109,876 $9.62 Million
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $398,252 - $532,921
-5,428 Reduced 4.63%
111,856 $11 Million
Q1 2020

May 12, 2020

SELL
$64.5 - $97.79 $722,980 - $1.1 Million
-11,209 Reduced 8.72%
117,284 $8.94 Million
Q4 2019

Feb 18, 2020

BUY
$72.13 - $90.25 $187,321 - $234,379
2,597 Added 2.06%
128,493 $11.4 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $173,069 - $208,078
-2,748 Reduced 2.14%
125,896 $9.53 Million
Q2 2019

Aug 07, 2019

BUY
$65.7 - $83.98 $121,610 - $155,446
1,851 Added 1.46%
128,644 $9.36 Million
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $369,192 - $434,520
-4,786 Reduced 3.64%
126,793 $10.2 Million
Q4 2018

Feb 11, 2019

BUY
$77.85 - $96.01 $396,645 - $489,170
5,095 Added 4.03%
131,579 $12.1 Million
Q3 2018

Nov 15, 2018

BUY
$88.91 - $98.84 $299,982 - $333,486
3,374 Added 2.74%
126,484 $12 Million
Q2 2018

Aug 15, 2018

BUY
$89.78 - $106.23 $321,861 - $380,834
3,585 Added 3.0%
123,110 $11.4 Million
Q1 2018

Apr 25, 2018

BUY
$92.01 - $123.21 $4.03 Million - $5.4 Million
43,839 Added 57.92%
119,525 $11.3 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $59,109 - $64,818
-660 Reduced 0.86%
75,686 $7.32 Million
Q3 2017

Oct 05, 2017

BUY
$69.85 - $89.22 $2.12 Million - $2.71 Million
30,347 Added 65.97%
76,346 $6.78 Million
Q3 2017

Oct 02, 2017

BUY
$69.85 - $89.22 $3.21 Million - $4.1 Million
45,999
45,999 $4.09 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bridges Investment Management Inc Portfolio

Follow Bridges Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridges Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bridges Investment Management Inc with notifications on news.